doxazosin has been researched along with oxybutynin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alpendre, C; D'Ancona, CA; Ikari, LY; Natalin, R; Prudente, A; Reis, LO | 1 |
| Chapple, CR; Osman, NI | 1 |
| Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
| Bruschini, H; de Bessa, J; Gomes, CM; Hisano, M; Nahas, WC; Sammour, ZM; Srougi, M | 1 |
1 review(s) available for doxazosin and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for doxazosin and oxybutynin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Triple therapy in refractory detrusor overactivity: a preliminary study.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents, Tricyclic; Child; Doxazosin; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imipramine; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Prospective Studies; Urinary Bladder, Overactive; Young Adult | 2010 |
Lower urinary tract symptoms revisited.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Benzhydryl Compounds; Cresols; Cystitis, Interstitial; Doxazosin; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Tolterodine Tartrate | 2012 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
Longitudinal Improvement of Lower Urinary Tract Symptoms in Williams-Beuren Syndrome.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Child; Doxazosin; Female; Follow-Up Studies; Humans; Lower Urinary Tract Symptoms; Male; Mandelic Acids; Time Factors; Urological Agents; Williams Syndrome | 2021 |